Roivant Sciences (ROIV) Interest Coverage Ratio (2022 - 2024)
Roivant Sciences' (ROIV) quarterly Interest Coverage Ratio came in at 4639.89 in Q3 2025, down 156050.86% YoY from N/an in Q3 2024, and down 199.64% on a QoQ basis from 1548.49 in Q2 2025.
Analysis
Roivant Sciences (ROIV) Interest Coverage Ratio (2022 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Interest Coverage Ratio data on file, last reported at 4639.89 in Q3 2025.
- Quarterly Interest Coverage Ratio fell 156050.86% year-over-year to 4639.89 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 25018.14 (down 64469.86% YoY) and the FY2026 annual result came in at 0.32, up 77.46% from the prior year.
- Interest Coverage Ratio fell to 4639.89 in Q3 2025, from 1548.49 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 185.76 in Q4 2023 to a low of 4639.89 in Q3 2025.
- A 5-year average of 462.14 and a median of 26.86 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio jumped 482.76% — and 2025, when it slumped 156050.86%.
- Tracing ROIV's Interest Coverage Ratio over 5 years: stood at 194.9 in 2021, then jumped by 75.1% to 48.53 in 2022, then jumped by 482.76% to 185.76 in 2023, then slumped by 103.42% to 6.35 in 2024, then tumbled by 73019.14% to 4639.89 in 2025.
- The last three Interest Coverage Ratio figures came in at 4639.89 (Q3 2025), 1548.49 (Q2 2025), and 6.35 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Roivant Sciences | 25.18 Bn | 25.18 Bn | 1.16 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -7.63 |
| Dec 31, 2023 | 185.76 |
| Sep 30, 2023 | -23.13 |
| Jun 30, 2023 | -31.02 |
| Dec 31, 2022 | -48.53 |
| Sep 30, 2022 | -33.69 |
| Jun 30, 2022 | -108.08 |